title: A 84-month follow up of adherence to HAART in a cohort of adult Senegalese patients.
abstract: OBJECTIVE
  To assess long-term adherence of the first HIV-1 patients receiving highly active antiretroviral therapy (HAART) in Senegal, and to identify the main determinants of adherence.
  
  
  METHODS
  The first 180 patients enrolled in the Senegalese HAART initiative between August 1998 and April 2001 followed up for at least 30 days were eligible. Adherence was assessed monthly at each drug dispensation between November 1999 and November 2006 by a pharmacist using a pill count completed by a questionnaire. Adherence was expressed as the proportion of tablets taken to prescribed tablets. An adherence of 95% was considered to be good. A random-intercept logit model was fitted to identify the main determinants of adherence.
  
  
  RESULTS
  Adherence data were available for 158 of 167 eligible patients. Twenty-nine patients died during the study period and 10 were lost to follow-up. Median treatment duration was 78 months, accruing to 6657 person-months of observation. Overall, mean adherence reached 91% [median: 100%, interquartile range (IQR) 96-100%] and adherence exceeded 95% in 78% [95% CI 77-79%] of observations. After 4 years of treatment mean adherence stabilized around 90% and adherence > or =95% stabilized around 70%. Treatment duration and protease inhibitor (PI)-based regimen (indinavir) had a negative effect on adherence, but adherence tended to improve with time for patients receiving a PI. Patient-level variance was highly significant and accounted for a third of total variance.
  
  
  CONCLUSIONS
  This work demonstrates that good long-term adherence can be achieved in the sub-Saharan context given close monitoring and adherence support measures, confirms the worse adherence for indinavir and underlines the importance of patient heterogeneity.
authors.affiliation: UMR 145 HIV/AIDS and Associated Diseases, Research Institute for Development (IRD)/University of Montpellier, 911 avenue Agropolis, 34394 Montpellier Cedex 1, France. etard@mpl.ird.fr
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Etard
authors.forename: Isabelle
authors.initials: I
authors.lastname: Lanièce
authors.forename: Mame Basty Koita
authors.initials: MB
authors.lastname: Fall
authors.forename: Vannina
authors.initials: V
authors.lastname: Cilote
authors.forename: Laure
authors.initials: L
authors.lastname: Blazejewski
authors.forename: Karim
authors.initials: K
authors.lastname: Diop
authors.forename: Alice
authors.initials: A
authors.lastname: Desclaux
authors.forename: René
authors.initials: R
authors.lastname: Ecochard
authors.forename: Ibra
authors.initials: I
authors.lastname: Ndoye
authors.forename: Eric
authors.initials: E
authors.lastname: Delaporte
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance / Q000706:statistics & numerical data*; D012675:Senegal; D011795:Surveys and Questionnaires